LRRK2 Promotes Tau Accumulation, Aggregation and Release

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 3124-3135

  Guerreiro, Patrícia Silva ^a,b   Gerhardt, Ellen ^b   Lopes da Fonseca, Tomás ^a,b   Bähr, Mathias ^b   Outeiro, Tiago Fleming ^a,b   Eckermann, Katrin ^b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

LRRK2; Protein accumulation; Protein degradation; Tau

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PROTEASOME; TAU PROTEIN; PROTEIN AGGREGATE; PROTEIN BINDING;

ARTICLE; AUTOPHAGY; BIOACCUMULATION; CELL LEVEL; CELLULAR SECRETION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; BIOLOGICAL MODEL; HEK293 CELL LINE; METABOLISM;

AUTOPHAGY; HEK293 CELLS; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN AGGREGATES; PROTEIN BINDING; PROTEOLYSIS; TAU PROTEINS;

EID: 84930155887     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9209-z     Document Type: Article

References (52)

1. Paisán-Ruíz C et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600
2. Zimprich A et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–7
3. West AB et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102(46):16842–7
4. Ross OA et al (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol 10(10):898–908
5. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci 11(12):791–7
6. Greggio E (2012) Role of LRRK2 kinase activity in the pathogenesis of Parkinson’s disease. Biochem Soc Trans 40(5):1058–62
7. Greggio E et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23(2):329–41
8. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9(10):1231–3
9. Taymans JM, Cookson MR (2010) Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 32(3):227–35
10. Belluzzi E, Greggio E, Piccoli G (2012) Presynaptic dysfunction in Parkinson’s disease: a focus on LRRK2. Biochem Soc Trans 40(5):1111–6
11. Lichtenberg M, Mansilla A, Zecchini VR, Fleming A, Rubinsztein DC (2011) The Parkinson’s disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis 2, e196
12. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3(4):519–26
13. Schwalbe M et al (2013) Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2. Biochemistry 52(50):9068–79
14. Dolan PJ, Johnson GV (2010) The role of tau kinases in Alzheimer’s disease. Curr Opin Drug Discov Devel 13(5):595–603
15. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98(12):6923–8
16. Chesser AS, Pritchard SM, Johnson GV (2013) Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer Disease. Front Neurol 4:122
17. Lee MJ, Lee JH, Rubinsztein DC (2013) Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol 105:49–59
18. Hamano T, Gendron TF, Ko LW, Yen SH (2009) Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy. Int J Clin Exp Pathol 2(6):561–73
19. Krüger U, Wang Y, Kumar S, Mandelkow EM (2012) Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 33(10):2291–305
20. Moreau K et al (2014) PICALM modulates autophagy activity and tau accumulation. Nat Commun 22(5):4998
21. Kawakami F et al (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 7(1), e30834
22. Kawakami F et al (2014) Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β. FEBS J 281(1):3–13
23. Bailey RM et al (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126(6):809–27
24. Gonçalves SA, Matos JE, Outeiro TF (2010) Zooming into protein oligomerization in neurodegeneration using BiFC. Trends Biochem Sci 35(11):643–51
25. Ramirez A et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38(10):1184–91
26. Saha S, Liu-Yesucevitz L, Wolozin B (2014) Regulation of autophagy by LRRK2 in Caenorhabditis elegans. Neurodegener Dis 13(2-3):110–3
27. Bence NF, Bennett EJ, Kopito RR (2005) Application and analysis of the GFPu family of ubiquitin-proteasome system reporters. Methods Enzymol 399:481–90
28. Kisselev AF, Goldberg AL (2005) Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 398:364–78
29. Tapiola T et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–9
30. Guerreiro PS et al (2013) LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models. J Mol Med (Berl) 91(4):513–22
31. Venderova K et al (2009) Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson’s disease. Hum Mol Genet 18(22):4390–404
32. Nichols RJ et al (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430(3):393–404
33. Reyniers L et al (2014) Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J Neurochem. doi:10.1111/jnc.12798
34. Melrose HL et al (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40(3):503–17
35. Matenia D, Mandelkow EM (2009) The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci 34(7):332–42
36. Herzig MC et al (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 7(5), e36581
37. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86(8):1711–20
38. Parisiadou L et al (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29(44):13971–80
39. Law BM et al (2014) A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem 289(2):895–908
40. Gillardon F (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability—a point of convergence in parkinsonian neurodegeneration? J Neurochem 110(5):1514–22
41. Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 85(1):115–22
42. Giasson BI et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636–40
43. Chaunu MP et al (2013) Juvenile frontotemporal dementia with parkinsonism associated with tau mutation G389R. J Alzheimers Dis 37(4):769–76
44. David DC et al (2002) Proteasomal degradation of tau protein. J Neurochem 83(1):176–85
45. Wang Y, Mandelkow E (2012) Degradation of tau protein by autophagy and proteasomal pathways. Biochem Soc Trans 40(4):644–52
46. Manzoni C et al (2013) Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun 441(4):862–6
47. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105(3):1048–56
48. Kondo K, Obitsu S, Teshima R (2011) α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol Pharm Bull 34(7):1078–83
49. Simón D, García-García E, Royo F, Falcón-Pérez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 586(1):47–54
50. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287(23):19440–51
51. Fraser KB et al (2013) LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet 22(24):4988–5000
52. Holmberg CI et al (2004) Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23(21):4307–18